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Abstract
Introduction: Critical illness leads to increased endogenous production of carbon monoxide (CO) due to the
induction of the stress-response enzyme, heme oxygenase-1 (HO-1). There is evidence for the cytoprotective and
anti-inflammatory effects of CO based on animal studies. In critically ill patients after cardiothoracic surgery, low
minimum and high maximum carboxyhemoglobin (COHb) levels were shown to be associated with increased
mortality, which suggests that there is an ‘optimal range’ for HO-1 activity. Our study aimed to test whether this
relationship between COHb and outcome exists in non-surgical ICU patients.
Methods: We conducted a retrospective, observational study in a medical ICU at a university hospital in Vienna,
Austria involving 868 critically ill patients. No interventions were undertaken. Arterial COHb was measured on
admission and during the course of treatment in the ICU. The association between arterial COHb levels and ICU
mortality was evaluated using bivariate tests and a logistic regression model.
Results: Minimum COHb levels were slightly lower in non-survivors compared to survivors (0.9%, 0.7% to 1.2%
versus 1.2%, 0.9% to 1.5%; P = 0.0001), and the average COHb levels were marginally lower in non-survivors
compared to survivors (1.5%, 1.2% to 1.8% versus 1.6%, 1.4% to 1.9%, P = 0.003). The multivariate logistic regression
analysis revealed that the association between a low minimum COHb level and increased mortality was
independent of the severity of illness and the type of organ failure.
Conclusions: Critically ill patients surviving the admission to a medical ICU had slightly higher minimum and
marginally higher average COHb levels when compared to non-survivors. Even though the observed differences
are statistically significant, the minute margins would not qualify COHb as a predictive marker for ICU mortality.
Introduction
CO is synthesized naturally in the body and serves a
range of physiological functions including vasodilation,
angiogenesis, vascular remodeling, protection against tis-
sue damage and modulation of the inflammatory
response [1,2]. Approximately 85% of the CO is pro-
duced by heme oxygenase (HO), which catalyses heme
to CO, iron and biliverdin. Biliverdin is further broken
down into bilirubin [3]. The major site of heme catabo-
lism, and thus CO production, is the liver [4]. The nor-
mal blood COHb saturation in non-smokers is
approximately 1% [5], the mean saturation in smokers
of approximately 20 cigarettes per day lies around 5.5%
[6]. The majority of CO is removed from the body via
expiration [7]. Of the two isoforms of heme oxygenase
(HO-1, HO-2), HO-1 is the only inducible isoform [8];
it is induced by oxidative stress, hypoxia, heavy metals,
sodium arsenite, heme and heme derivatives, as well as
by cytokines [9-11].
Increased expression of HO-1 and elevated COHb
levels have been demonstrated in patients with critical
disease, chronic obstructive pulmonary disease (COPD),
systemic inflammatory response syndrome and acute
respiratory distress syndrome [12-14]. HO-1 induction
may be beneficial because its products possess anti-
inflammatory and antioxidant properties [15,16]. How-
ever, excessive HO-1 activity is deleterious, possibly due
to the liberation of molecular iron [17]. Melley et al.
observed that patients who were admitted to an ICU fol-
lowing cardiothoracic surgery were more likely to die in
the ICU if they had lower minimum or higher maxi-
mum COHb levels [18], thus supporting the hypothesis
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that there is an optimal range for HO-1 induction [17].
Of interest, inhaled CO is also currently being tested as
a therapeutic agent based on evidence of cytoprotective
and anti-inflammatory effects from animal studies. The
observed peak levels of COHb in these preclinical stu-
dies typically range from 5% to 30% [19]. However, the
therapeutic potential of CO in humans is limited by its
toxicity. For example, even low levels of 2% to 6%
COHb decrease exercise time to angina or produce an
increase in arrhythmias in non-smoking patients with
known coronary artery disease [20,21]. On the other
hand, healthy volunteers have been shown to tolerate
levels of 12% to 14% without serious side effects [19].
We proposed the following hypothesis for our study:
because abnormal COHb levels correlate with an
increased ICU mortality in critically ill medical patients,
COHb would serve as a predictive marker for ICU mor-
tality. In addition, detailed knowledge about the charac-
teristics of COHb levels in critically ill patients would be




The study was observational and retrospective in nature.
All non-surgical patients who were consecutively
admitted to one of the ICUs of the General Hospital of
Vienna between December 3, 2001 and September 26,
2005 were considered for inclusion. Because no addi-
tional interventions were undertaken and analysis was
performed on anonymous data, the need for informed
consent was waived. The local ethics committee
approved the study. The exclusion criteria included pre-
vious admissions to the ICU, planned withdrawal of
therapy within 24 hours, and a surgical cause for
admission.
Data collection
Results from point of care analyzers for every patient
who was admitted to the ICU were automatically down-
loaded into a computerized clinical information system.
Collected data were manually checked for accuracy and
were linked to the patients’ medical record numbers.
The admitting physician manually recorded the reason
for admission in the patient files. Patients were assigned
to a distinct admission category based on the recorded
reason for admission [22].
Laboratory assays
COHb levels were determined immediately upon ICU
admission and every four to six hours thereafter using a
heparinized blood sample that was collected from an
indwelling arterial catheter. The point of care analyzer
runs a zero calibration of the optical system against a
colorless calibration fluid at least every four hours to
guarantee accuracy.
Severity of illness and ICU outcome
Severity of illness was assessed by the Simplified Acute
Physiology Score II (SAPS II) [23]. Scoring was per-
formed on the worst values that were recorded in the
24 hours following admission to the ICU using the data
retrieved from the computerized clinical information
system. The outcome variables measured included ICU
mortality and ICU length of stay. Furthermore, the pre-
sence of organ failure in the respiratory, circulatory,
renal, hepatic, and cerebral system was recorded based
on Sepsis-related Organ Failure Assessment (SOFA) cri-
teria [24].
Data analysis
Data are presented as median and interquartile ranges
or as mean and standard deviation. Minimum, maxi-
mum, average and area under the curve values as well
as the variance for measured COHb levels were calcu-
lated according to the Melley study [18]. Statistical tests
and mathematical modeling were performed using
PASW v18. Correlation in normally distributed variables
was calculated by Pearson’s coefficient. Multivariate
logistic regression was performed using the vital status
upon ICU discharge as the response variable and the
COHb level as the primary exposure variable. Predefined
confounding variables were included in the initial
regression model, including the SAPS II score, the
admission category, the presence and type of organ fail-
ure, and the age and gender of the patients. Models
were subsequently refined by backward exclusion.
To compare serial COHb measurements according to
ICU survival, we used a generalized estimating equation
assuming a first order exponential correlation matrix for
repeated observations within one patient.
For all analyses statistical significance was defined by a
two-sided P < 0.05.
Results
Admission characteristics
The study flow chart is presented in Figure 1. A total of
1,416 patients (1,483 admissions) were admitted to the
ICU during the 46-month study period. The analysis
was restricted to the first admission for the 67 patients
with multiple ICU admissions; 481 patients were
excluded from the analysis (Figure 1).
The causes of admission and the types of organ failure
in the remaining 868 patients are shown in Table 1.
There were 525 (60%) male patients, and the median
age of the patients was 59 years old (47 to 70). The
median SAPS II score was 49 (34 to 62). The median
length of ICU stay was 6 days (3 to 11), and 220
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patients (25%) died in the ICU. SAPS II scores were sig-
nificantly higher in the group of non-survivors. There
was no difference in age between the two patient
groups. Circulatory, renal, hepatic, and cerebral failure
was significantly and independently associated with ICU
mortality, whereas respiratory failure did not show a
correlation (Table 2).
COHb levels in the entire cohort
The mean COHb level in all patients was 1.6% (1.3% to
1.9%), which was elevated compared to healthy non-
smokers (approximately 0.8%) but considerably less than
the COHb levels in current smokers (approximately 6%
to 8%) [5]. The minimum and maximum COHb levels
were 1.1% (0.8% to 1.4%) and 2.1% (1.7% to 2.6%),
respectively, in each patient. The complete
characteristics of the COHb levels including the variance
and area under the curve results are shown in Table 3.
COHb levels according to admission category and
severity of illness
Mean COHb differed between admission categories (Fig-
ure 2). Highest values were observed in patients with
renal and gastrointestinal disease. Lowest levels were
seen in the neurological and medical (not otherwise spe-
cified) categories.
Minimal COHb was inversely correlated with SAPS II
score (Pearson’s correlation coefficient with 95% confi-
dence intervals: 0.21 (0.14 to 0.27), P < 0.0001) (Figure
3). Therefore, patients who were severely ill on admis-
sion had lower minimal levels of COHb during the
course of their treatment in the ICU.
COHb levels andmortality
The non-survivors had a slightly lower minimum COHb
level compared to the survivors (0.9%, 0.7% to 1.2% ver-
sus 1.2%, 0.9% to 1.5%; P = 0.0001); therefore, the
patients who died had the lowest COHb levels. In addi-
tion, the mean COHb level was marginally lower in the
non-survivors (1.5%, 1.2% to 1.8% versus 1.6%, 1.4% to
1.9%; P = 0.003). During the first 72 hours after ICU
admission average COHb was 0.1% lower in patients
who died compared to patients who survived; P = 0.003.
Differences were most pronounced during the first 48
hours (Figure 4).
Patients treated at the 






- Readmission (n=67) 
- Therapy withdrawn 
within 24 hours (n=6) 
- Surgical type of 
admission (n=254) 
 
Incomplete data  (n=221) 
Figure 1 Study Flow Chart.
Table 1 Admission category and organ failure on
admission in the entire cohort.
Admission Category Number Percent (%)
Metabolic disease 4 0
Respiratory disease 234 27
Cardiovascular disease 204 24
Shock 6 1
Renal disease 23 3
Neurologic disease 74 9
Sepsis 80 9
Trauma (not operated) 3 0
Gastrointestinal disease 109 13
Hematologic disease 20 2
Medical, not otherwise specified 108 12
Pregnancy 3 0






Organ failure was defined according to SOFA criteria [24]
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Table 2 Admission category and organ failure according to the survival status.
ICU survivors (n = 648) ICU non-survivors (n = 220)
Number % Number %
Admission Category Metabolic disease 4 1 0 0
Respiratory disease 196 30 38 17
Cardiovascular disease 155 24 49 22
Shock 2 0 4 2
Renal disease 21 3 2 1
Neurologic disease 61 9 13 6
Sepsis 44 7 36 16
Trauma (not operated) 2 0 1 0
Gastrointestinal disease 75 12 34 15
Hematologic disease 14 2 6 3
Medical, not otherwise specified 71 11 37 17
Pregnancy 3 0 0 0
P-value
Organ Failure Respiratory 472 73 166 75 0.45
Circulatory 290 45 164 75 0.0001
Renal 158 24 112 51 0.0001
Hepatic 124 19 80 36 0.0001
Cerebral 265 41 108 49 0.034
Table 3 COHb in the entire cohort, values expressed as % of total hemoglobin
Mean Standard-deviation Median Percentile 25 Percentile 75
COHb minimum 1.1 0.5 1.1 0.8 1.4
COHb maximum 2.2 0.8 2.1 1.7 2.6
COHb mean 1.6 0.5 1.6 1.3 1.9
COHb variance 0.1 0.3 0.1 0 0.1
COHb area under curve 1.6 0.5 1.6 1.3 1.9
AUC, area under the curve.
Figure 2 Mean carboxyhemoglobin during the stay on the ICU according to the admission category. P < 0.0001 in univariate ANOVA.
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The maximum COHb level did not differ between the
two groups (survivors 2.1%, 1.7% to 2.6% versus non-
survivors 2.1%, 1.5% to 2.5%; P = 0.19). The COHb var-
iance was marginally smaller in the survivors compared
to the non-survivors (0.0%, 0.0 to 0.1% versus 0.1%, 0.0
to 0.1%; P = 0.0001). The COHb area under the curve
results were marginally higher in the survivors com-
pared to the non-survivors (1.6%, 1.4% to 1.9% versus
1.5%, 1.2% to 1.8%; P = 0.01).
The association between a low minimum COHb level
and increased mortality was independent of the severity
of illness and the type of organ failure on ICU admis-
sion. The results of the multivariate logistic regression
are shown in Table 4.
Discussion
Our study shows that the minimum and average COHb
levels are marginally higher in medical patients who
survive an episode of critical illness compared to non-
survivors. The study by Melley et al. showed that the
minimum COHb level was significantly higher in
patients who survived a short ICU stay (median 1.0 (0.9
to 2.8) days) following cardiothoracic surgery compared
to patients who died in the ICU [18]. This association
was reproduced in our patient cohort of general medical
patients who required longer ICU stays (median 6 (3 to
11) days). Furthermore, the maximum COHb level was
associated with an increased mortality in the Melley
study (P < 0.001 in univariate analysis and P = 0.08 in
multivariate analysis); however, this association was not
reproduced in our study.
Our study also shows differences in COHb levels
according to admission category with patients
admitted with renal and gastrointestinal disease having
the highest levels. However, further data would be
needed to draw pathophysiological conclusions from
Figure 3 Correlation between minimal carboxyhemoglobin during the stay on the ICU with SAPS II score. Pearson’s correlation
coefficient with 95% confidence intervals: 0.21 (0.14 to 0.27), P < 0.0001. The line and error bars (95% confidence intervals) are derived from
linear regression.
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this observation. The expected correlation between
SAPS II score and COHb level was seen in our study
with sicker patients having lower minimal COHb
levels.
The strengths of our study include the enrollment of a
large patient cohort and being the first study to analyze
COHb levels in non-surgical patients who were
admitted to a general medical ICU. The limitations of
Figure 4 Mean levels of COHb during the first 72 hours after admission to the ICU. Empty and full triangles represent non-survivors and
survivors, respectively. In order to prevent overlap black triangles were shifted to the right by 1.2 hours.
Table 4 Logistic regression analysis of the association between minimal COHb level and ICU mortality
Odds ratio and 95% confidence intervals P-value
COHb minimum, % 0.6 (0.4 to 0.8) 0.001
SAPSII score 1.0 (1.0 to 1.0) < 0.001
Cardiovascular failure on ICU admission, yes/no 2.2 (1.6 to 3.3) < 0.001
Renal failure on ICU admission, yes/no 1.8 (1.2 to 2.6) 0.003
Hepatic failure on ICU admission, yes/no 1.8 (1.2 to 2.7) 0.003
SAPS II score and the type of organ failure on admission were predefined confounders.
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our study include the paucity of data on the smoking
status and history of respiratory disease prior to admis-
sion, the bilirubin and Hb levels, the inhaled oxygen
concentration during the course of the admission and
the hospital outcome following ICU discharge. We
acknowledge that these limitations need to be taken into
account when interpreting our results. Arguably, a
strong correlation between arterial COHb, exhaled car-
bon monoxide (eCO) and total serum bilirubin as
indices of heme metabolism exists in critically ill
patients [25]; therefore, we would like to suggest that
the absence of bilirubin levels does not hamper the
quality of our data. On the other hand, we take into
account that the lack of data on smoking status might
represent a bias in our study. Current smokers have
approximately five-fold higher COHb levels than the
observed average COHb levels in our study [6]. Of inter-
est, very few of our patients had COHb levels above
2.5%. We speculate that a considerable amount of the
smokers’ CO has been washed out prior to admission to
the ICU as the state of their illness did not allow them
to smoke in the hours prior to the admission.
Overall, it remains unclear whether there is an actual
causal effect of COHb levels on survival. The anti-
inflammatory products of HO-1 induction might be
beneficial [26]. Failure to activate protective systems
including HO-1 in the face of inflammatory conditions
may be deleterious. Indeed, variants of the promoter
region of the HO-1 gene with an increased activity were
recently found to be associated with a reduced risk for
the development of adult respiratory distress syndrome
[27].
The observed differences in COHb levels between sur-
vivors and non-survivors in our study were statistically
significant and indicate that this may be an important
pathway. On the other hand, given the relative minute-
ness of the differences in COHb between the two
groups, we have to conclude that COHb does not qua-
lify as a predictive marker for ICU mortality. Neverthe-
less, we hope that the presented data add to a more
complete understanding of the characteristics of COHb
in medical intensive care patients.
Conclusion
Critically ill patients surviving the admission to a medi-
cal ICU had slightly higher minimum and marginally
higher average COHb levels when compared to non-sur-
vivors. Observed margins were minute and do not qua-
lify COHb as a marker for ICU mortality.
Key messages
• Non-surgical patients surviving critical illness had
slightly higher minimum and marginally higher aver-
age COHb levels compared to patients who died.
• Observed margins were minute and would not
qualify COHb as a marker for ICU mortality.
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